Next Article in Journal
Small Volume Dissolution Testing as a Powerful Method during Pharmaceutical Development
Previous Article in Journal
Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny
Pharmaceutics 2010, 2(4), 339-350; doi:10.3390/pharmaceutics2040339
Article

Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids

1, 1, 2, 3 and 3,*
Received: 21 September 2010; in revised form: 20 October 2010 / Accepted: 26 October 2010 / Published: 27 October 2010
View Full-Text   |   Download PDF [262 KB, uploaded 27 October 2010]   |   Browse Figures
Abstract: Several biologically relevant phospholipids were assessed as potential carriers/additives for rapidly dissolving solid formulations of piroxicam (Biopharmaceutics Classification System Class II drug). On the basis of in vitro dissolution studies, dimyristoylphosphatidylglycerol (DMPG) was ranked as the first potent dissolution rate enhancer for the model drug. Subsequently, the solid dispersions of varying piroxicam/DMPG ratios were prepared and further investigated. Within the concentration range studied (6.4-16.7 wt %), the dissolution rate of piroxicam from the solid dispersions appeared to increase as a function of the carrier weight fraction, whereas the cumulative drug concentration was not significantly affected by piroxicam/DMPG ratio, presumably due to a unique phase behavior of the aqueous dispersions of this carrier phospholipid. Solid state analysis of DMPG-based formulations reveled that they are two-component systems, with a less thermodynamically stable form of piroxicam (Form II) being dispersed within the carrier. Finally, oral bioavailability of piroxicam from the DMPG-based formulations in rats was found to be superior to that of the control, as indicated by the bioavailability parameters, cmax and especially Tmax (53 µg/mL within 2 h vs. 39 µg/mL within 5.5 h, respectively). Hence, DMPG was regarded as the most promising carrier phospholipid for enhancing oral bioavailability of piroxicam and potentially other Class II drugs.
Keywords: poorly water soluble drugs; phospholipids; solid dispersions; dissolution; bioavailability poorly water soluble drugs; phospholipids; solid dispersions; dissolution; bioavailability
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Mirza, S.; Miroshnyk, I.; Habib, M.J.; Brausch, J.F.; Hussain, M.D. Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. Pharmaceutics 2010, 2, 339-350.

AMA Style

Mirza S, Miroshnyk I, Habib MJ, Brausch JF, Hussain MD. Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. Pharmaceutics. 2010; 2(4):339-350.

Chicago/Turabian Style

Mirza, Sabiruddin; Miroshnyk, Inna; Habib, Muhammad J.; Brausch, James F.; Hussain, Muhammad D. 2010. "Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids." Pharmaceutics 2, no. 4: 339-350.


Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert